Analyst Ratings For Sinclair Pharma PLC (LON:SPH)
Today, Peel Hunt reiterated its Buy rating on Sinclair Pharma PLC (LON:SPH) with a price target of GBX 68.
There are 6 buy ratings on the stock.
The current consensus rating on Sinclair Pharma PLC (LON:SPH) is Buy (Score: 3.00) with a consensus target price of GBX 57.20 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-Peel Hunt Reiterated Rating of Buy.
- 11/18/2016-Canaccord Genuity Reiterated Rating of Buy.
- 10/5/2016-N+1 Singer Reiterated Rating of Buy.
- 9/21/2016-Stifel Nicolaus Reiterated Rating of Buy.
- 9/15/2016-Royal Bank of Canada Reiterated Rating of Outperform.
- 9/28/2015-Panmure Gordon Reiterated Rating of Under Review.
About Sinclair Pharma PLC (LON:SPH)
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor. The Company’s product categories include Aesthetic Care, Skin Care, Wound Care and Non-Dermatology. The Company provides aesthetic dermatology solutions through thread lift, collagen stimulation and dermal fillers. The Company’s aesthetic products include Silhouette Soft, Ellanse, Perfectha, Sculptra and USOFT Massage Gel. Its Silhouette Soft is inserted in the subcutaneous tissue. Its USOFT Massage Gel is a gel used for facial massage. It is engaged in research and development, and owns various product rights and licenses in a range of territories in which it trades.
Recent Trading Activity for Sinclair Pharma PLC (LON:SPH)
Shares of Sinclair Pharma PLC closed the previous trading session at 32.50 up +0.75 2.36% with 55,000 shares trading hands.
